Claims
- 1. A method of inhibiting endothelial cell proliferation in a human or animal comprising administering to the human or animal a therapeutically active dosage of a composition comprising an efrapeptin oligopeptide in a pharmaceutically acceptable carrier.
- 2. The method of claim 1 wherein the endothelial cell proliferation occurs during angiogenesis-related disease.
- 3. The method of claim 2 wherein the angiogenesis-related disease is a disease selected from the group consisting of cancer, endometriosis, Kaposis's sarcoma, arthritis, atherosclerosis, psoriasis, macular degeneration, and diabetic retinopathy.
- 4. A method of inhibiting endothelial cell proliferation occurring during an angiogenesis-related disease in a human or animal comprising administering to the human or animal a therapeutically active dosage of a composition comprising of aurovertin B, citreoviridin, or α-zearalenol in a pharmaceutically acceptable carrier.
- 5. The method of claim 4 wherein the angiogenesis-related disease is a disease selected from the group consisting of cancer, endometriosis, Kaposis's sarcoma, arthritis, atherosclerosis, psoriasis, macular degeneration, and diabetic retinopathy.
Parent Case Info
The present nonprovisional patent application claims benefits of provisional patent application entitled “Mycotoxin derivatives as antimitotic agents” with filing date Sep. 23, 1999 and patent application Ser. No. 60/155,625.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4842862 |
Jacobs et al. |
Jun 1989 |
A |
5003056 |
Nishikiori et al. |
Mar 1991 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
4-26631 |
Jan 1992 |
JP |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/155625 |
Sep 1999 |
US |